The Company intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin (AEZS-108) program, secondly for its macimorelin acetate (AEZS-130) program, including the preparation of its commercial launch, as well as for the potential addition of commercialized products to the Company's pipeline, future negative cash flow, general corporate purposes and working capital.
The current cash holding should last them till Q3 of next year i beileve. So i can see why they r wanting to raise more cash for aezs-130. I am however not happy about the timing of this. They should have done it before the nda filing or after the approval .... gl
they are ready to file for bankruptcy. the bankruptcy will be triggered when the NDA gets rejected. till then they will extract as much as they can of the shareholder value. that's why they were in no hurry to file NDA